Zelicapavir is a small molecule commercialized by Enanta Pharmaceuticals, with a leading Phase II program in Respiratory Syncytial Virus (RSV) Infections. According to Globaldata, it is involved in 12 clinical trials, of which 9 were completed, 2 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Zelicapavir’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Zelicapavir is expected to reach an annual total of $106 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Zelicapavir Overview
Enanta Pharmaceuticals Overview
Enanta Pharmaceuticals (Enanta) is a clinical-stage biotechnology company that develops small molecule drugs for viral and immune infections. The company’s pipeline products include glecaprevir is protease inhibitor that targets hepatitis C virus (HCV); EDP-514 core inhibitor treats hepatitis B virus (HBV); EDP-938 N-protein inhibitor for the respiratory syncytial virus (RSV); EDP-323 and EDP-235 are L-protein inhibitor and 3CL protease inhibitors that targets respiratory syncytial virus and COVID-19. It works in partnership with the National Institute of Allergy and Infectious Diseases, AbbVie Inc, Novartis and Shionogi Inc to discover two protease inhibitor compounds. Enanta is headquartered in Watertown, Massachusetts, the US.
The company reported revenues of (US Dollars) US$79.2 million for the fiscal year ended September 2023 (FY2023), a decrease of 8.1% over FY2022. The operating loss of the company was US$137.2 million in FY2023, compared to an operating loss of US$123.8 million in FY2022. The net loss of the company was US$133.8 million in FY2023, compared to a net loss of US$121.8 million in FY2022.
The company reported revenues of US$18 million for the third quarter ended June 2024, an increase of 5.4% over the previous quarter.
For a complete picture of Zelicapavir’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
